Clinical Trials Logo

Basal Cell Carcinoma (BCC) clinical trials

View clinical trials related to Basal Cell Carcinoma (BCC).

Filter by:
  • None
  • Page 1

NCT ID: NCT02750033 Withdrawn - Clinical trials for Basal Cell Carcinoma (BCC)

Intraoperative Margin Assessment During Mohs Surgery

Start date: October 2016
Phase:
Study type: Observational

The research team will develop an intraoperative handheld device for assessing surgical margins during Mohs surgery. The device technology is based on multimodal optical spectroscopy (MMS), combining three optical spectroscopy techniques into one device. The researchers will first acquire proof of concept MMS measurements within the Mohs surgery suite immediately after surgical excision and prior to histological processing. MMS measurements will be acquired directly on the patient from the NMSC excision site. The final outcome of this study will result in the sensitivity and specificity of MMS compared to histopathology during Mohs surgery. These results will allow for the estimation of the potential benefit of an intraoperative margin assessment technique.

NCT ID: NCT02144077 Completed - Clinical trials for Basal Cell Carcinoma (BCC)

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Start date: January 28, 2014
Phase: Phase 3
Study type: Interventional

The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).

NCT ID: NCT01633515 Recruiting - Clinical trials for Basal Cell Carcinoma (BCC)

Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study

Start date: July 2012
Phase: N/A
Study type: Interventional

A feasibility study for the treatment of Basal Cell Carcinoma of the lower extremities in the elderly utilizing intralesional cryosurgery. 10 cases of BCC (confirmed by biopsy) in the lower extremity of elderly will undergo intralesional cryotherapy. A Cryoneedle is introduced through the skin lesion (BCC) and thus the BCC is frozen. Treatment success will be determined according to biopsy results 3 months after treatment

NCT ID: NCT01108094 Completed - Skin Cancer Clinical Trials

Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Basal cell carcinomas (BCCs) are the most common human cancer in the US and affect over 1 million people. There is no effective drug to prevent basal cell carcinomas of the skin. We hope to learn if an oral anti-fungal drug, itraconazole, might inhibit a marker of proliferation and a biomarker (tumor signaling pathway) of BCC development. Itraconazole is an FDA-approved drug for the treatment of fungal infections of the skin, and has been used for the past 25 years with relatively few side effects. It has been shown in mice to reduce a BCC biomarker and to reduce growth of BCCs. Thus, it may reduce BCC growth in humans.

NCT ID: NCT00670189 Completed - Clinical trials for Basal Cell Carcinoma (BCC)

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule